Central Nervous System Neoplasms

The supplied grounding does not support a single unified cause for central nervous system neoplasms. It does indicate that some entities are associated with specific genetic profiles and that familial tumor syndromes, including rhabdoid tumor predisposition syndrome, can involve the nervous system.

These neoplasms reflect abnormal neoplastic growth within central nervous system tissues, with biological behavior varying by tumor type and grade. The literature highlights that molecular alterations are now integrated into classification because they help define tumor identity, pathophysiology, and clinical behavior.

The supplied grounding does not support general risk factors for all central nervous system neoplasms. It does note familial tumor syndromes involving the nervous system and tumor-specific genetic alterations as relevant to classification and prognosis.

Management is described at the level of diagnosis, therapy, and drug therapy, with treatment depending on tumor type, grade, and molecular features. The literature supports multimodal neuro-oncology care, including surgery and other tumor-directed therapies, and for malignant tumors it emphasizes molecularly informed management and clinical trial participation where appropriate.